Tifcemalimab
Tifcemalimab (JS004) is a humanized anti-BTLA (B and T lymphocyte attenuation factor) monoclonal antibody. Tifcemalimab blocks the interaction of HVEM-BTLA by binding to BTLA, and thus blocks the inhibitory signaling pathway mediated by BTLA. Tifcemalimab can be used in research of cancer, such as lymphoma and non-small cell lung cancer (NSCLC) [1][2].
Product Specifications
CAS Number
[2236068-83-8]
Product Name Alternative
JS004; Icatolimab
UNSPSC
12352203
Target
CD28
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/tifcemalimab.html
Purity
96.02
Solubility
10 mM in DMSO
Smiles
[Tifcemalimab]
Molecular Weight
(146 kDa)
References & Citations
[1]Jun Ma, et al. Phase I Study of the Anti-Btla Antibody Tifcemalimab As a Single Agent or in Combination with Toripalimab in Relapsed/Refractory Lymphomas. Blood (2022) 140 (Supplement 1) : 3716–3717.|[2]D. Lv, et al. Tifcemalimab combined with toripalimab and docetaxel as 2nd line treatment for immunotherapy-treated squamous cell non-small cell lung cancer (Sq-NSCLC) patients: A phase Ib/II study - Annals of Oncology. Volume 35, Supplement 4S1645December 2024.
Shipping Conditions
Dry Ice
Storage Conditions
Store at -80°C for 2 years
Scientific Category
Inhibitory Antibodies
Clinical Information
Phase 3
Available Sizes
Curated Selection
Explore Other Products
Discover premium biology products from our extensive collection of 20M+ items
TR313504 1 Kit
Density RegµLated Protein (DENR) Human shRNA Plasmid Kit (Locus ID 8562)
Ask
View Details 
217618 10 mg
P38 MAP Kinase Inhibitor XI (4- (2,4-Difluorophenyl) -8- (2-methylphenyl) -1,7-naphthyridine-7-oxide, 4- (2,4-Difluorophenyl) -8-o-tolyl-1,7-naphthyridine-7-oxide) discontinued
Ask
View Details